1. Introduction {#sec1}
===============

Stroke, an acute cerebrovascular disease, is the leading cause of death and disability worldwide, especially in Asia \[[@B1]\]. It has been traditionally considered that stroke, especially atherosclerotic ischemic stroke, is closely associated with hypercoagulability, such as increased homocysteine and lipoprotein(a) and antiphospholipid antibodies \[[@B2]\]. Liver cirrhosis, which often has an increased level of factor VIII (FVIII) and decreased level of protein C (PC) and mean lifetime of platelet, has been also considered as a potential risk factor of stroke \[[@B3], [@B4]\]. Besides, it is associated with the development of venous thromboembolism, including portal vein thrombosis \[[@B5]\].

Development of stroke and portal vein thrombosis in liver cirrhosis seems to share several common pathophysiological mechanisms or risk factors. First, both of them relate to the hypercoagulability of cirrhosis \[[@B3]\], which is characterized as reduced PC in combination with increased FVIII \[[@B6]\]. Second, both stroke and portal vein thrombosis relate to portal hypertension. Reduced portal vein flow velocity and portosystemic collateral shunt are common characteristics of portal hypertension, which aggravate the development of portal vein thrombosis \[[@B7]\]. Ascites and esophageal variceal bleeding are major clinical manifestations of portal hypertension, which result in the decrease of effective circulating blood volume and hypovolemia of organs, thereby leading to ischemic stroke \[[@B8]\]. Third, diabetic patients have approximately 2-4 times higher risk of ischemic stroke than those with normal glucose levels \[[@B9]\]. Meanwhile, diabetes is also an independent risk factor of portal vein thrombosis \[[@B10]\]. Fourth, antiphospholipid syndrome may increase the risk of ischemic stroke as well as portal vein thrombosis. Irregular thickening of the valve leaflets secondary to antiphospholipid syndrome and lupus anticoagulants are significant risk factor of stroke \[[@B11]\]. Meanwhile, anticardiolipin antibodies levels were higher in liver cirrhosis with portal vein thrombosis than that without portal vein thrombosis \[[@B12], [@B13]\]. Fifth, Helicobacter pylori not only acts as a promoter of antiphospholipid syndrome through chronic inflammation \[[@B14]\] but also stimulates the production of plasminogen activator inhibitor-2, which has an effect on increasing the risk of ischemic stroke and portal vein thrombosis \[[@B15]\]. Sixth, methylenetetrahydrofolate reductase (MTHFR) mutation is a common risk factor of stroke and portal vein thrombosis, which relates to endothelial damage \[[@B16]\]. MTHFR activity is reduced in the patients with MTHFR mutations, thereby leading to the deficiency of folate and hyperhomocysteinemia. MTHFR is responsible for catalyzing the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in the folate cycle, which further produces the active form of folate for the remethylation of homocysteine to methionine \[[@B17]\]. There is a significant association between hyperhomocysteinemia and stroke \[[@B18]\]. An elevated homocysteine concentration significantly increases the risk of stroke \[[@B19]\]. Folic acid supplementation is effective in stroke prevention \[[@B20]\]. And MTHFR A1298C mutation is associated with increased risk of ischemic stroke \[[@B21]\]. On the other hand, MTHFR C677T mutation may increase the risk of portal vein thrombosis in cirrhotic patients \[[@B22]\]. The prevalence of hyperhomocysteinemia is significantly higher in cirrhotic patients with portal vein thrombosis than those without portal vein thrombosis \[[@B22]\]. Taken together, we hypothesized that cirrhotic patients with stroke might have an increased risk of portal vein thrombosis. Herein, this retrospective study was aimed at elucidating this issue.

2. Methods {#sec2}
==========

2.1. Study Design {#sec2.1}
-----------------

The study population was selected from our prospectively established database of cirrhotic patients without malignancy of the Department of Gastroenterology of our hospital from December 2014 to July 2019. All included patients must undergo abdominal enhanced computed tomography or magnetic resonance and endoscopy at their first enrollment. Age, sex, and the etiologies of liver cirrhosis were not limited. Repeated admissions of the same patients were excluded. Patients with abdominal surgery, including splenectomy, and splenic arterial embolization were excluded. Patients in whom a history of stroke cannot be accurately evaluated were excluded. Patients in whom the location of portal vein thrombosis cannot be evaluated due to missing images were also excluded. The study protocol was approved by the Medical Ethics Committee of our hospital. The ethical approval number was k(2019)39. The patient\'s informed consent was not required in our retrospective study.

2.2. Medical Data {#sec2.2}
-----------------

The data were collected as follows. Demographic information: age and sexSystolic and diastolic blood pressure at admissionEtiologies of liver diseases: hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol abuse, drug related liver diseases, Budd-Chiari syndrome, and autoimmune liver diseases, etc.Clinical presentations at admission: hepatic encephalopathy, acute gastrointestinal bleeding, and ascitesMedical history: venous thrombus, hematological diseases, diabetes mellitus, arterial hypertension, smoking, and cardiac diseasesLaboratory tests: red blood cell, hemoglobin, white blood cell, platelet, total bilirubin, direct bilirubin, indirect bilirubin, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, *γ*-glutamyl transpeptidase, blood urea nitrogen, serum, creatinine, potassium, sodium homocysteine, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, lipoprotein *α*, prothrombin time, international normalized ratio (INR), activated partial thromboplastin time, D-dimer, antithrombin III, PC activity, and PS activityChild-Pugh and model for the end-stage liver diseases (MELD) score

2.3. Definitions {#sec2.3}
----------------

Stroke was defined as previous history of stroke as well as a diagnosis of stroke at their enrollment. Type of stroke was divided into ischemic and hemorrhagic stroke according to previous medical history, clinical manifestations, and/or the results of brain imaging examination. Location of portal vein thrombosis was determined by our study group via the images of enhanced computed tomography or magnetic resonance. Portal system vessels include left portal vein (LPV), right portal vein (RPV), main portal vein (MPV), confluence of superior mesenteric vein (SMV) and splenic vein (SV), SMV, and SV.

2.4. Statistical Analyses {#sec2.4}
-------------------------

Continuous and categorical variables were expressed by median (range) and frequency (percentage), respectively. The difference between patients with and without stroke was compared using Mann-Whitney *U* test and *χ*^2^ test, as appropriate. A 1 : 1 propensity score matching (PSM) analysis was performed to adjust the effect of age, sex, Child-Pugh score, and MELD score on our statistical results. If a *p* value was less than 0.05, it would be considered statistically significant. SPSS statistical software, version 22.0 (IBM Corp, Armonk, NY, USA), was employed to perform statistical analyses.

3. Results {#sec3}
==========

3.1. Patients\' Characteristics {#sec3.1}
-------------------------------

Overall, 349 cirrhotic patients were included, of whom 31 (8.88%) had stroke and 318 did not have stroke. Among the 31 patients with stroke, 29 (8.31%), 4 (1.15%), and 2 (0.57%) patients had ischemic stroke, hemorrhagic stroke, and hemorrhagic combined with ischemic stroke, respectively. The prevalence of portal vein thrombosis was 28.65% (100/349). The prevalence of thrombosis within LPV, RPV, MPV, confluence of SMV and SV, SMV, and SV was 8.31% (29/349), 9.46% (33/349), 16.05% (56/349), 11.46% (40/349), 15.19% (53/349), and 3.72% (13/349), respectively.

3.2. Comparison between Liver Cirrhosis with and without Stroke {#sec3.2}
---------------------------------------------------------------

Compared with the patients without stroke, those with stroke were significantly older (60.21 versus 54.21 years, *p* = 0.003) and had significantly higher proportions of alcohol abuse (64.5% versus 43.7%, *p* = 0.026), smoking (67.7% versus 42.5%, *p* = 0.007), and arterial hypertension (38.7% versus 12.9%, *p* \< 0.001) and higher levels of white blood cell (4.50 versus 3.40 × 10^9^/L, *p* = 0.001) and low-density lipoprotein (2.12 versus 1.65 mmol/L, *p* = 0.013) ([Table 1](#tab1){ref-type="table"}). There was no difference in the prevalence of portal vein thrombosis and location of portal vein thrombosis between patients with and without stroke.

3.3. Comparison between Cirrhotic Patients with Ischemic Stroke and Those without Stroke {#sec3.3}
----------------------------------------------------------------------------------------

Compared with the patients without stroke, those with ischemic stroke were significantly older (61.08 versus 54.21 years, *p* = 0.002) and had significantly higher proportions of alcohol abuse (65.5% versus 43.7%, *p* = 0.024), smoking (69.0% versus 42.5%, *p* = 0.006), and arterial hypertension (37.9% versus 12.9%, *p* \< 0.001) and higher levels of white blood cell (4.90 versus 3.40 × 10^9^/L, *p* \< 0.001), potassium (4.05 versus 3.86 mmol/L, *p* = 0.047), and low-density lipoprotein (2.12 versus 1.65 mmol/L, *p* = 0.008) ([Table 2](#tab2){ref-type="table"}). There was no significant difference in the prevalence of portal vein thrombosis and location of portal vein thrombosis between patients with and without stroke.

3.4. PSM Analysis between Cirrhotic Patients with Ischemic Stroke and Those without Stroke {#sec3.4}
------------------------------------------------------------------------------------------

Twenty-eight patients were matched in each group after a 1 : 1 PSM analysis ([Table 3](#tab3){ref-type="table"}). There was no significant difference in demographics, etiology of liver disease, laboratory tests, clinical presentations, Child-Pugh score, and MELD score between the two groups. Notably, we still did not find any significant association between ischemic stroke and portal vein thrombosis.

4. Discussion {#sec4}
=============

Recently, a large population-based cohort study using Danish National Patient Registry demonstrated that splanchnic vein thrombosis significantly increased the risk of bleeding and arterial cardiovascular events as compared to patients with venous thromboembolism and general population \[[@B23]\]. In this study, splanchnic vein thrombosis referred to venous thrombosis within the portal, hepatic, mesenteric, and splenic veins; and arterial cardiovascular events included unstable angina pectoris, acute myocardial infarction, and ischemic stroke. They included 1,915 patients with splanchnic vein thrombosis, of whom 1,711 patients had portal vein thrombosis. They found that patients with splanchnic vein thrombosis had higher risk of bleeding and arterial cardiovascular events up to 1 year after diagnosis. In contrast to these findings, we did not find any significant association between stroke and portal vein thrombosis in liver cirrhosis, even in the PSM analysis. There were several potential reasons for this unexpected phenomenon. First, HCV infection, which should be regarded as a possible causative factor in the antiphospholipid syndrome with an increased prevalence of anticardiolipin antibodies \[[@B24]\] and an aggravated risk of hypercoagulability, is more prevalent in Western countries; by comparison, in our Chinese patients, HBV infection is the major etiology of liver cirrhosis, and the prevalence of HCV infection was only 6.02% (21/349) in our patients, which might lead to a low probability of antiphospholipid syndrome. Second, because Helicobacter pylori is an indirect risk factor of hypercoagulation and is not routinely detected in liver cirrhosis, our study did not have such data and could not compare the difference in the prevalence of Helicobacter pylori infection between patients with and without stroke. Third, our study demonstrated that the level of homocysteine was higher in patients with stroke or ischemic stroke than in patients without stroke, but the difference was not significant. This finding should be validated by expanding the number of patients who underwent laboratory tests of homocysteine levels.

Our study had several limitations. First, the number of our study population, especially patients with ischemic stroke, might not be adequate. Among the patients admitted to our Department of Gastroenterology, most of stroke events are usually asymptomatic. Therefore, in our retrospective observational study, the imaging examination of the brain has not been performed in every cirrhotic patient to evaluate the risk of asymptomatic stroke. Indeed, the imaging examination of the brain in every cirrhotic patient might not be approved by any ethical committee. Herein, the history of asymptomatic stroke, such as lacunar infarction, might be missed. Second, in the present study, we selected study population from a prospectively established database, in which only the patients undergoing enhanced computed tomography or magnetic resonance are included. Although enhanced computed tomography or magnetic resonance can evaluate more precisely the existence, extent, and degree of portal vein thrombosis, there was a potential bias in patient selection in this setting. Third, hypercoagulability is not evaluated in all patients. Fourth, Helicobacter pylori infection, which may be associated with both portal vein thrombosis and stroke, has not been studied in our study.

In conclusion, our study could not establish any association between stroke and portal vein thrombosis in liver cirrhosis. Certainly, well-designed large-scale prospective cohort studies will be necessary to confirm this finding.

We are indebted to our study team for establishing and updating our prospective database, including Han Deng, Ran Wang, Qianqian Li, Xiangbo Xu, Zhaohui Bai, Yanyan Wu, Li Luo, Shixue Xu, Yanglan He, and Yingying Li, of whom all had worked for our study group.
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###### 

Comparison between patients with and without stroke.

  Variables                                          Stroke   No stroke                        *p* value                                        
  -------------------------------------------------- -------- -------------------------------- ----------- ------------------------------------ -----------
  Age (years)                                        31       60.21 (38.72-77.30)              318         54.21 (20.57-88.73)                  *0.003*
  Gender (male)                                      31       25 (80.6%)                       318         230 (72.3%)                          0.319
  Systolic blood pressure (mmHg)                     31       125.00 (90.00-173.00)            317         122.00 (83.00-193.00)                0.594
  Diastolic blood pressure (mmHg)                    31       75.00 (50.00-117.00)             317         75.00 (34.00-118.00)                 0.844
  Etiology of liver diseases                                                                                                                    
   Hepatitis B virus infection                       31       10 (32.3%)                       318         125 (39.3%)                          0.442
   Hepatitis C virus infection                       31       1 (3.2%)                         318         20 (6.3%)                            0.494
   Alcohol abuse                                     31       20 (64.5%)                       318         139 (43.7%)                          *0.026*
   Drug related                                      31       4 (12.9%)                        318         21 (6.6%)                            0.194
   Budd-Chiari syndrome                              31       0 (0.0%)                         318         1 (0.3%)                             0.755
   Autoimmune liver diseases                         31       0 (0.0%)                         318         22 (6.9%)                            0.130
  Clinical presentations at admission                                                                                                           
   Hepatic encephalopathy                            31       1 (3.2%)                         318         8 (2.5%)                             0.812
   Acute gastrointestinal bleeding                   31       9 (29.0%)                        318         101 (31.8%)                          0.755
   Ascites (no/mild/moderate-severe)                 31       16 (51.6%)/8 (25.8%)/7 (22.6%)   318         127 (39.9%)/108 (34.0%)/83 (26.1%)   0.440
  History                                                                                                                                       
   History of venous thrombus                        31       0 (0.0%)                         318         7 (2.2%)                             0.404
   History of hematological diseases                 31       1 (3.2%)                         318         5 (1.6%)                             0.499
   History of diabetes mellitus                      31       8 (25.8%)                        318         51 (16.0%)                           0.166
   History of arterial hypertension                  31       12 (38.7%)                       318         41 (12.9%)                           *\<0.001*
   History of smoking                                31       21 (67.7%)                       318         135 (42.5%)                          0.007
   History of cardiac diseases                       31       5 (16.1%)                        318         23 (7.2%)                            0.082
  Laboratory tests                                                                                                                              
   Red blood cell (10^12^/L)                         31       3.33 (1.15-5.20)                 318         3.27 (1.45-5.46)                     0.432
   Hemoglobin (g/L)                                  31       101.00 (37.00-174.00)            318         92.50 (28.00-156.00)                 0.104
   White blood cell (10^9^/L)                        31       4.50 (1.30-22.70)                318         3.40 (0.70-20.80)                    *0.001*
   Platelet (10^9^/L)                                31       86.00 (37.00-377.00)             318         73.00 (19.00-470.00)                 0.169
   Total bilirubin (*μ*mol/L)                        31       21.10 (5.70-132.70)              318         22.00 (5.20-281.10)                  0.775
   Direct bilirubin (*μ*mol/L)                       31       8.90 (2.00-78.20)                318         9.45 (2.00-210.40)                   0.920
   Indirect bilirubin (*μ*mol/L)                     31       11.90 (3.60-76.00)               318         11.30 (3.20-93.80)                   0.677
   Albumin (g/L)                                     31       32.50 (22.10-44.50)              316         32.35 (14.20-50.60)                  0.482
   Alanine aminotransferase (U/L)                    31       20.06 (7.74-176.68)              318         24.34 (4.23-613.24)                  0.396
   Aspartate aminotransferase (U/L)                  31       30.73 (9.74-143.00)              318         34.33 (9.63-761.63)                  0.824
   Alkaline phosphatase (U/L)                        31       88.23 (28.83-337.00)             318         94.40 (31.00-983.93)                 0.641
   *γ*-Glutamyl transpeptidase (U/L)                 31       70.00 (10.00-1779.18)            318         42.64 (7.54-1283.02)                 0.121
   Blood urea nitrogen (mmol/L)                      31       5.85 (3.52-47.25)                314         5.31 (0.64-24.80)                    0.226
   Serum creatinine (*μ*mol/L)                       31       70.90 (42.82-267.63)             314         64.07 (23.83-178.55)                 0.228
   Potassium (mmol/L)                                31       4.01 (2.80-5.41)                 317         3.86 (2.42-5.28)                     0.066
   Sodium (mmol/L)                                   31       138.00 (134.10-145.50)           317         138.90 (118.00-152.90)               0.574
   Homocysteine (*μ*mol/L)                           16       10.49 (6.70-31.79)               170         9.16 (1.59-102.81)                   0.145
   Total cholesterol (mmol/L)                        20       3.68 (1.82-6.58)                 208         3.11 (1.14-6.29)                     0.148
   Triglyceride (mmol/L)                             20       0.83 (0.41-6.22)                 208         0.85 (0.35-4.81)                     0.661
   High-density lipoprotein (mmol/L)                 20       0.93 (0.47-1.39)                 208         0.94 (0.24-2.29)                     0.766
   Low-density lipoprotein (mmol/L)                  20       2.12 (0.99-4.37)                 208         1.65 (0.47-4.06)                     *0.013*
   Lipoprotein *α* (mg/L)                            20       88.70 (17.90-466.40)             208         63.20 (3.60-911.40)                  0.108
   Prothrombin time (seconds)                        31       15.30 (12.70-20.40)              314         15.70 (10.30-28.00)                  0.188
   International normalized ratio                    31       1.23 (0.99-1.75)                 314         1.27 (0.89-2.77)                     0.164
   Activated partial thromboplastin time (seconds)   31       40.20 (19.80-53.80)              314         39.90 (23.10-71.30)                  0.808
   D-dimer (mg/L)                                    19       1.32 (0.16-10.56)                252         0.86 (0.10-46.17)                    0.873
   Antithrombin III (%)                              11       65.30 (40.00-84.00)              118         63.00 (21.00-123.00)                 0.933
   Protein C activity (%)                            6        57.30 (49.80-75.10)              54          59.65 (24.00-119.30)                 0.721
   Protein S activity (%)                            6        61.55 (55.60-73.30)              54          63.50 (20.70-123.60)                 0.873
  Child-Pugh score                                   31       7.00 (5.00-10.00)                313         7.00 (5.00-13.00)                    0.837
  MELD score                                         31       10.46 (7.23-18.00)               312         10.41 (6.43-30.03)                   0.736
  Portal vein thrombosis                             31       8 (25.8%)                        318         92 (28.9%)                           0.713
   LPV                                                        4 (12.9%)                                    25 (7.9%)                            0.332
   RPV                                                        2 (6.5%)                                     31 (9.7%)                            0.549
   MPV                                                        4 (12.9%)                                    52 (16.4%)                           0.617
   Confluence of SMV and SV                                   5 (16.1%)                                    35 (11.0%)                           0.393
   SMV                                                        2 (6.5%)                                     51 (16.0%)                           0.156
   SV                                                         0 (0.0%)                                     13 (4.1%)                            0.251

No. pts: number of patients; MELD: model for the end-stage liver diseases; LPV: left portal vein; RPV: right portal vein; MPV: main portal vein; SMV: superior mesenteric vein; SV: splenic vein.

###### 

Comparison between patients with ischemic stroke and those without stroke.

  Variables                                          Ischemic stroke   No stroke                        *p* value                                        
  -------------------------------------------------- ----------------- -------------------------------- ----------- ------------------------------------ -----------
  Age (years)                                        29                61.08 (38.72-77.30)              318         54.21 (20.57-88.73)                  *0.002*
  Gender (male)                                      29                23 (79.3%)                       318         230 (72.3%)                          0.418
  Systolic blood pressure (mmHg)                     29                124.00 (90.00-173.00)            317         122.00 (83.00-193.00)                0.975
  Diastolic blood pressure (mmHg)                    29                73.00 (50.00-108.00)             317         75.00 (34.00-118.00)                 0.700
  Etiology of liver diseases                                                                                                                             
   Hepatitis B virus infection                       29                10 (34.5%)                       318         125 (39.3%)                          0.610
   Hepatitis C virus infection                       29                1 (3.4%)                         318         20 (6.3%)                            0.539
   Alcohol abuse                                     29                19 (65.5%)                       318         139 (43.7%)                          *0.024*
   Drug related                                      29                4 (13.8%)                        318         21 (6.6%)                            0.152
   Budd-Chiari syndrome                              29                0 (0.0%)                         318         1 (0.3%)                             0.762
   Autoimmune liver diseases                         29                0 (0.0%)                         318         22 (6.9%)                            0.143
  Clinical presentations at admission                                                                                                                    
   Hepatic encephalopathy                            29                1 (3.4%)                         318         8 (2.5%)                             0.762
   Acute gastrointestinal bleeding                   29                8 (27.6%)                        318         101 (31.8%)                          0.643
   Ascites (no/mild/moderate-severe)                 29                15 (51.7%)/7 (24.1%)/7 (24.1%)   318         127 (39.9%)/108 (34.0%)/83 (26.1%)   0.424
  History                                                                                                                                                
   History of venous thrombus                        29                0 (0.0%)                         318         7 (2.2%)                             0.420
   History of hematological diseases                 29                1 (3.4%)                         318         5 (1.6%)                             0.458
   History of diabetes mellitus                      29                8 (27.6%)                        318         51 (16.0%)                           0.113
   History of arterial hypertension                  29                11 (37.9%)                       318         41 (12.9%)                           *\<0.001*
   History of smoking                                29                20 (69.0%)                       318         135 (42.5%)                          *0.006*
   History of cardiac diseases                       29                5 (17.2%)                        318         23 (7.2%)                            0.058
  Laboratory tests                                                                                                                                       
   Red blood cell (10^12^/L)                         29                3.33 (1.15-5.20)                 318         3.27 (1.45-5.46)                     0.471
   Hemoglobin (g/L)                                  29                101.00 (37.00-174.00)            318         92.50 (28.00-156.00)                 0.126
   White blood cell (10^9^/L)                        29                4.90 (1.30-22.70)                318         3.40 (0.70-20.80)                    *\<0.001*
   Platelet (10^9^/L)                                29                90.00 (37.00-377.00)             318         73.00 (19.00-470.00)                 0.068
   Total bilirubin (*μ*mol/L)                        29                25.10 (5.70-132.70)              318         22.00 (5.20-281.10)                  0.606
   Direct bilirubin (*μ*mol/L)                       29                9.00 (2.00-78.20)                318         9.45 (2.00-210.40)                   0.892
   Indirect bilirubin (*μ*mol/L)                     29                12.40 (3.60-76.00)               318         11.30 (3.20-93.80)                   0.576
   Albumin (g/L)                                     29                31.10 (22.10-44.50)              316         32.35 (14.20-50.60)                  0.401
   Alanine aminotransferase (U/L)                    29                21.33 (7.74-176.68)              318         24.34 (4.23-613.24)                  0.643
   Aspartate aminotransferase (U/L)                  29                31.44 (9.74-143.00)              318         34.33 (9.63-761.63)                  0.902
   Alkaline phosphatase (U/L)                        29                92.49 (28.83-337.00)             318         94.40 (31.00-983.93)                 0.921
   *γ*-Glutamyl transpeptidase (U/L)                 29                70.00 (10.00-1779.18)            318         42.64 (7.54-1283.02)                 0.073
   Blood urea nitrogen (mmol/L)                      29                5.82 (3.52-47.25)                314         5.31 (0.64-24.80)                    0.271
   Serum creatinine (*μ*mol/L)                       29                70.90 (42.82-267.63)             314         64.07 (23.83-178.55)                 0.253
   Potassium (mmol/L)                                29                4.05 (2.80-5.41)                 317         3.86 (2.42-5.28)                     *0.047*
   Sodium (mmol/L)                                   29                137.90 (134.10-145.50)           317         138.90 (118.00-152.90)               0.430
   Homocysteine (*μ*mol/L)                           15                10.47 (6.70-31.79)               170         9.16 (1.59-102.81)                   0.179
   Total cholesterol (mmol/L)                        19                3.77 (1.82-6.58)                 208         3.11 (1.14-6.29)                     0.104
   Triglyceride (mmol/L)                             19                0.86 (0.47-6.22)                 208         0.85 (0.35-4.81)                     0.414
   High-density lipoprotein (mmol/L)                 19                0.92 (0.47-1.39)                 208         0.94 (0.24-2.29)                     0.762
   Low-density lipoprotein (mmol/L)                  19                2.12 (0.99-4.37)                 208         1.65 (0.47-4.06)                     *0.008*
   Lipoprotein *α* (mg/L)                            19                91.70 (17.90-466.40)             208         63.20 (3.60-911.40)                  0.114
   Prothrombin time (seconds)                        29                15.30 (12.70-20.40)              314         15.70 (10.30-28.00)                  0.198
   International normalized ratio                    29                1.23 (0.99-1.75)                 314         1.27 (0.89-2.77)                     0.170
   Activated partial thromboplastin time (seconds)   29                40.00 (19.80-53.80)              314         39.90 (23.10-71.30)                  0.952
   D-dimer (mg/L)                                    19                1.32 (0.16-10.56)                252         0.86 (0.10-46.17)                    0.873
   Antithrombin III (%)                              11                65.30 (40.00-84.00)              118         63.00 (21.00-123.00)                 0.933
   Protein C activity (%)                            6                 57.30 (49.80-75.10)              54          59.65 (24.00-119.30)                 0.721
   Protein S activity (%)                            6                 61.55 (55.60-73.30)              54          63.50 (20.70-123.60)                 0.873
  Child-Pugh score                                   29                7.00 (5.00-10.00)                313         7.00 (5.00-13.00)                    0.749
  MELD score                                         29                10.46 (7.23-18.00)               312         10.41 (6.43-30.03)                   0.892
  Portal vein thrombosis                             29                7 (24.1%)                        318         92 (28.9%)                           0.584
   LPV                                                                 3 (10.3%)                                    25 (7.9%)                            0.638
   RPV                                                                 2 (6.9%)                                     31 (9.7%)                            0.616
   MPV                                                                 4 (13.8%)                                    52 (16.4%)                           0.720
   Confluence of SMV and SV                                            5 (17.2%)                                    35 (11.0%)                           0.314
   SMV                                                                 2 (6.9%)                                     51 (16.0%)                           0.190
   SV                                                                  0 (0.0%)                                     13 (4.1%)                            0.267

No. pts: number of patients; MELD: model for the end-stage liver diseases; LPV: left portal vein; RPV: right portal vein; MPV: main portal vein; SMV: superior mesenteric vein; SV: splenic vein.

###### 

Characteristics of cirrhotic patients with ischemic stroke and those without stroke after propensity score matching.

  Variables                                          Overall (*n* = 56)                 Ischemic stroke (*n* = 28)       No stroke (*n* = 28)             *p* value
  -------------------------------------------------- ---------------------------------- -------------------------------- -------------------------------- -----------
  Age (years)                                        59.68 (35.18-77.30)                60.65 (38.72-77.30)              58.44 (35.18-75.72)              0.258
  Gender (male)                                      47 (83.9%)                         22 (78.6%)                       25 (89.3%)                       0.275
  Systolic blood pressure (mmHg)                     125.00 (83.00-173.00)              124.50 (90.00-173.00)            126.50 (83.00-158.00)            0.491
  Diastolic blood pressure (mmHg)                    75.50 (44.00-108.00)               72.00 (50.00-108.00)             81.00 (44.00-107.00)             0.161
  Etiology of liver diseases                                                                                                                              
   Hepatitis B virus infection                       23 (41.1%)                         10 (35.7%)                       13 (46.4%)                       0.415
   Hepatitis C virus infection                       1 (1.8%)                           1 (3.6%)                         0 (0.0%)                         0.313
   Alcohol abuse                                     35 (62.5%)                         18 (64.3%)                       17 (60.7%)                       0.783
   Drug related                                      6 (10.7%)                          4 (14.3%)                        2 (7.1%)                         0.388
   Budd-Chiari syndrome                              0 (0.0%)                           0 (0.0%)                         0 (0.0%)                         NA
   Autoimmune liver diseases                         1 (1.8%)                           0 (0.0%)                         1 (3.6%)                         0.313
  Clinical presentations at admission                                                                                                                     
   Hepatic encephalopathy                            2 (3.6%)                           1 (3.6%)                         1 (3.6%)                         1.000
   Acute gastrointestinal bleeding                   13 (23.2%)                         7 (25.0%)                        6 (21.4%)                        0.752
   Ascites (no/mild/moderate-severe)                 27 (48.2%)/14 (25.0%)/15 (26.8%)   15 (53.6%)/6 (21.4%)/7 (25.0%)   12 (42.9%)/8 (28.6%)/8 (28.6%)   0.710
  History                                                                                                                                                 
   History of venous thrombus                        0 (0.0%)                           0 (0.0%)                         0 (0.0%)                         NA
   History of hematological diseases                 1 (1.8%)                           1 (3.6%)                         0 (0.0%)                         0.313
   History of diabetes mellitus                      12 (21.4%)                         8 (28.6%)                        4 (14.3%)                        0.193
   History of arterial hypertension                  13 (23.2%)                         10 (35.7%)                       3 (10.7%)                        0.027
   History of smoking                                39 (69.6%)                         20 (71.4%)                       19 (67.9%)                       0.771
   History of cardiac diseases                       8 (14.3%)                          5 (17.9%)                        3 (10.7%)                        0.445
  Laboratory tests                                                                                                                                        
   Red blood cell (10^12^/L)                         3.52 (1.15-5.20)                   3.34 (1.15-5.20)                 3.69 (1.74-5.08)                 0.456
   Hemoglobin (g/L)                                  109.00 (37.00-174.00)              102.00 (37.00-174.00)            110.50 (58.00-156.00)            0.812
   White blood cell (10^9^/L)                        4.25 (1.30-22.70)                  4.70 (1.30-22.70)                4.05 (1.30-20.80)                0.063
   Platelet (10^9^/L)                                84.50 (37.00-423.00)               88.00 (37.00-377.00)             75.00 (37.00-423.00)             0.961
   Total bilirubin (*μ*mol/L)                        24.25 (5.70-132.70)                25.30 (5.70-132.70)              24.15 (6.60-47.00)               0.718
   Direct bilirubin (*μ*mol/L)                       9.55 (2.00-78.20)                  9.30 (2.00-78.20)                9.60 (2.50-27.00)                0.961
   Indirect bilirubin (*μ*mol/L)                     12.45 (3.60-76.00)                 12.60 (3.60-76.00)               12.35 (4.10-27.70)               0.967
   Albumin (g/L)                                     32.55 (22.10-46.20)                30.75 (22.10-44.50)              33.95 (24.50-46.20)              0.201
   Alanine aminotransferase (U/L)                    24.79 (7.53-176.68)                21.66 (7.74-176.68)              25.59 (7.53-140.00)              0.793
   Aspartate aminotransferase (U/L)                  33.94 (9.74-166.49)                34.22 (9.74-143.00)              33.94 (13.94-166.49)             0.857
   Alkaline phosphatase (U/L)                        98.86 (28.83-337.00)               93.60 (28.83-337.00)             102.83 (52.28-337.00)            0.481
   *γ*-Glutamyl transpeptidase (U/L)                 60.87 (10.00-1779.18)              69.50 (10.00-1779.18)            56.00 (10.93-552.26)             0.611
   Blood urea nitrogen (mmol/L)                      5.62 (2.96-47.25)                  5.81 (3.52-47.25)                5.38 (2.96-20.15)                0.502
   Serum creatinine (*μ*mol/L)                       66.64 (42.82-267.63)               68.96 (42.82-267.63)             64.19 (44.50-117.53)             0.870
   Potassium (mmol/L)                                3.99 (2.74-5.41)                   4.03 (2.80-5.41)                 3.89 (2.74-4.75)                 0.517
   Sodium (mmol/L)                                   138.50 (133.50-145.50)             137.95 (134.10-145.50)           139.65 (133.50-145.20)           0.210
   Prothrombin time (seconds)                        15.30 (12.70-20.40)                15.30 (12.70-20.40)              15.25 (12.00-18.90)              0.774
   International normalized ratio                    1.24 (0.93-1.75)                   1.24 (0.99-1.75)                 1.24 (0.93-1.64)                 0.883
   Activated partial thromboplastin time (seconds)   40.10 (19.80-53.80)                40.10 (19.80-53.80)              40.30 (27.50-50.80)              0.961
  Child-Pugh score                                   7.00 (5.00-10.00)                  7.00 (5.00-10.00)                7.00 (5.00-13.00)                0.259
  MELD score                                         10.43 (6.43-18.00)                 10.52 (7.23-18.00)               10.32 (6.43-15.58)               0.676
  Portal vein thrombosis                             14 (25.0%)                         7 (25.0%)                        7 (25.0%)                        1.000

MELD: model for the end-stage liver diseases.

[^1]: Academic Editor: Eberval G. Figueiredo
